drugset / Trial / NCT01707316

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

NCT01707316

Phase 1 Completed 15 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication) and pharmacodynamics (the action of the medication on the body) of JNJ-28431754 (canagliflozin) and its main metabolites (break-down products) following 2 different doses of canagliflozin in healthy Chinese volunteers. Safety and tolerability of canagliflozin will also be assessed.

Timeline

Start
2012-06
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral

Indications

No indication recorded.